Status:
TERMINATED
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Hodgkin Lymphoma, Follicular Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) di...
Eligibility Criteria
Inclusion
- Aged \>/= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Life expectancy of at least 12 weeks
- Histologically documented FL or DLBCL that has relapsed or failed to respond to at least two prior systemic treatment regimens and for which no suitable therapy of curative intent or higher priority exists (e.g., standard chemotherapy, ASCT, CAR T cells)
- At least one bi-dimensionally measurable (\> 1.5 cm) nodal lesion, or at least one bi-dimensionally measurable (\> 1.0 cm) extranodal lesion
- Participants with FL (including trFL) for whom a bone marrow biopsy and aspirate can be collected
- Adequate hematologic and organ function
Exclusion
- Received any of the following treatments prior to study entry: mosunetuzumab or other CD20/CD3-directed bispecific antibodies; tiragolumab or other anti-TIGIT agent; allogenic SCT; solid organ transplantation
- Currently eligible for autologous SCT
- Current or past history of CNS lymphoma or leptomeningeal infiltration
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- Contraindication to atezolizumab (if applicable) or tocilizumab
- Clinically significant toxicities from prior treatment have not resolved to Grade \</= 1 (per NCI CTCAE v5.0) prior to the first study drug administration with exceptions defined by the protocol
- Treatment-emergent immune-mediated adverse events associated with prior immunotherapeutic agents as defined by the protocol
- Evidence of any significant, concomitant disease as defined by the protocol
- Major surgery within 4 weeks prior to first study treatment administration, with the exception of protocol-mandated procedures (e.g., tumor biopsies and bone marrow biopsies)
- Significant cardiac, pulmonary, CNS, or liver disease, or known active infections
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- History of autoimmune disease with exceptions as defined in the protocol
Key Trial Info
Start Date :
May 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 19 2023
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT05315713
Start Date
May 10 2022
End Date
July 19 2023
Last Update
October 4 2024
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
2
University of Michigan
Ann Arbor, Michigan, United States, 48109
3
Lifespan Cancer Institute
Providence, Rhode Island, United States, 02905
4
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia, 2010